News Bad week for dementia R&D after Axovant howler and another f... Axovant misreports trial results, Lundbeck Alzheimer's drug fails
News Axovant axes dementia drug after disastrous trial results Intepirdine seemed to make symptoms worse in Lewy body disease
News Pfizer axes Alzheimer's and Parkinson's research Big pharma will continue developing tanezumab painkiller with Lilly
News GW files cannabis-based epilepsy drug in EU and US After Sativex disappointment, Epidiolex could transform GW's fortunes.
News NeuroPace brain implant reduces epilepsy seizures in long-te... Data also suggests treatment could improve memory
News Acorda axes Parkinson's drug after trial deaths Biotech not confident white blood cell counts could ensure patient safety.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
